ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year
Dosing Complete in the First Cohort of the Phase I BX2000 Study; On Track to Complete Enrollment in Remaining Cohorts by Early 2023
Read more at globenewswire.com